CY1629A - Lymphokine production and purification - Google Patents

Lymphokine production and purification

Info

Publication number
CY1629A
CY1629A CY1629A CY162992A CY1629A CY 1629 A CY1629 A CY 1629A CY 1629 A CY1629 A CY 1629A CY 162992 A CY162992 A CY 162992A CY 1629 A CY1629 A CY 1629A
Authority
CY
Cyprus
Prior art keywords
csf
cdna
preparing
protein
rna
Prior art date
Application number
CY1629A
Other languages
English (en)
Original Assignee
Sandoz Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27417446&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CY1629(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sandoz Ag filed Critical Sandoz Ag
Publication of CY1629A publication Critical patent/CY1629A/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/53—Colony-stimulating factor [CSF]
    • C07K14/535—Granulocyte CSF; Granulocyte-macrophage CSF
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/70—Vectors or expression systems specially adapted for E. coli
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/80—Vectors or expression systems specially adapted for eukaryotic hosts for fungi
    • C12N15/81—Vectors or expression systems specially adapted for eukaryotic hosts for fungi for yeasts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/44—Vectors comprising a special translation-regulating system being a specific part of the splice mechanism, e.g. donor, acceptor

Landscapes

  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Mycology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Saccharide Compounds (AREA)
  • Steroid Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Fats And Perfumes (AREA)
  • Compounds Of Unknown Constitution (AREA)
  • Debugging And Monitoring (AREA)
  • Detergent Compositions (AREA)
CY1629A 1984-07-06 1992-07-10 Lymphokine production and purification CY1629A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US62834284A 1984-07-06 1984-07-06
US65274284A 1984-09-19 1984-09-19
US65244784A 1984-09-19 1984-09-19

Publications (1)

Publication Number Publication Date
CY1629A true CY1629A (en) 1992-07-10

Family

ID=27417446

Family Applications (1)

Application Number Title Priority Date Filing Date
CY1629A CY1629A (en) 1984-07-06 1992-07-10 Lymphokine production and purification

Country Status (28)

Country Link
EP (2) EP0188479B1 (no)
JP (4) JP2540509B2 (no)
KR (1) KR910001809B1 (no)
AT (2) ATE172494T1 (no)
AU (3) AU599572B2 (no)
CA (2) CA1341618C (no)
CY (1) CY1629A (no)
DE (3) DE3588199T2 (no)
DK (2) DK168709B1 (no)
ES (1) ES8701226A1 (no)
FI (1) FI108796B (no)
GR (1) GR851643B (no)
HK (2) HK111594A (no)
HU (1) HU208711B (no)
IE (2) IE930961L (no)
IL (2) IL75725A (no)
LU (1) LU88337I2 (no)
MY (1) MY102902A (no)
NL (1) NL930089I2 (no)
NO (4) NO179455C (no)
NZ (2) NZ212645A (no)
PL (1) PL153139B1 (no)
PT (1) PT80776B (no)
SA (1) SA94150015A (no)
SG (1) SG108991G (no)
SK (1) SK280265B6 (no)
UA (1) UA39161C2 (no)
WO (1) WO1986000639A1 (no)

Families Citing this family (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU594014B2 (en) * 1984-03-21 1990-03-01 Research Corporation Technologies, Inc. Recombinant DNA molecules
JPS61227526A (ja) * 1984-07-25 1986-10-09 Chugai Pharmaceut Co Ltd 新規なコロニー刺激因子
AU588819B2 (en) * 1984-10-29 1989-09-28 Immunex Corporation Cloning of human granulocyte-macrophage colony stimulating factor gene
ZA856108B (en) * 1984-10-29 1986-10-29 Immunex Corp Cloning of human granulocyte-macrophage colony simulating factor gene
IL77080A (en) * 1984-11-20 1998-02-08 Schering Biotech Corp Polypeptides showing activity of human growth factor of macrophage granulocyte and eosinophils Vectors and cells transformed for their preparation and pharmaceutical preparations containing or
ATE80894T1 (de) * 1985-02-05 1992-10-15 Cetus Oncology Corp Reinigung des natuerlichen kolonie-stimulierenden faktors-1.
EP0220520B1 (en) * 1985-09-30 1991-09-18 Chugai Seiyaku Kabushiki Kaisha Human granulocyte colony stimulating factor
JPS63502795A (ja) * 1985-10-03 1988-10-20 バイオジェン インコーポレイテッド 顆粒球‐マクロファージコロニー刺激因子‐様ポリペプチド、ｄｎａ配列、組換えｄｎａ分子並びに微生物細胞中でヒト顆粒球−マクロファ−ジコロニ−刺激因子−様ポリペプチドを高収量で生産する方法
CA1295567C (en) * 1988-07-25 1992-02-11 Lawrence T. Malek Expression system for the secretion of bioactive human granulocyte, macrophage-colony stimulating factor (gm-csf) and other heterologous proteins from streptomyces
DE3545568A1 (de) * 1985-12-21 1987-07-16 Hoechst Ag Gm-csf-protein, seine derivate, herstellung solcher proteine und ihre verwendung
US5298603A (en) * 1985-12-21 1994-03-29 Hoechst Aktiengesellschaft GM-CSF protein, its derivatives, the preparation of proteins of this type, and their use
IL83003A (en) 1986-07-01 1995-07-31 Genetics Inst Factors that soak bone formation
GR871029B (en) 1986-07-14 1987-11-02 Genetics Inst Novel osteoinductive factors
US5162111A (en) * 1986-07-30 1992-11-10 Grabstein Kenneth H Treatment of bacterial diseases with granulocyte-macrophage colony stimulating factor
AU7675487A (en) * 1986-08-11 1988-05-19 Cetus Corporation Expression of granulocyte colony-stimulating factor
GB8624899D0 (en) * 1986-10-17 1986-11-19 Sandoz Ltd Monoclonal antibodies
JPH0618781B2 (ja) * 1986-10-18 1994-03-16 中外製薬株式会社 感染症治療剤
EP0276846A3 (en) * 1987-01-29 1989-07-26 Zymogenetics, Inc. Colony-stimulating factor derivatives
JP2521094B2 (ja) * 1987-04-28 1996-07-31 アムジェン、インコーポレーテッド ヒト顆粒球マクロファ―ジコロニ―刺激因子をコ―ドする合成ｄｎａ、そのｄｎａを含むプラスミド、およびそのｄｎａで形質転換された大腸菌
AU602097B2 (en) * 1987-06-25 1990-09-27 Immunex Corporation Bovine granulocyte-macrophage colony stimulating factor
ATE79884T1 (de) * 1987-07-16 1992-09-15 Schering Corp Reinigung von gm-csf.
US5391706A (en) * 1987-07-16 1995-02-21 Schering Plough Corporation Purification of GM-CSF
NZ225411A (en) * 1987-07-17 1991-04-26 Schering Biotech Corp Hgm-csf human granulocyte macrophage colony stimulating factor and vector for its expression containing the sr#a# promoter of the plasmid deposited in atcc67318
AU626530B2 (en) * 1987-07-17 1992-08-06 Schering Biotech Corporation Human granulocyte-macrophage colony stimulating factor and muteins thereof
WO1989001038A1 (en) * 1987-07-24 1989-02-09 Cetus Corporation PRODUCTION OF BIOLOGICALLY ACTIVE FORMS OF CSF USING A BACULOVIRUS (AcNPV)-INSECT CELL EXPRESSION SYSTEM
JPH03502582A (ja) * 1988-05-31 1991-06-13 シェリング・バイオテック・コーポレーション 骨髄性白血病の治療方法
AU618283B2 (en) * 1988-10-10 1991-12-19 Instituto Nazionale Per Lo Studio E La Cura Dei Tumori The use of GM-CSF in the treatment of a patient requiring high-dose chemo- or radiotherapy for cancer
US5811523A (en) 1988-11-10 1998-09-22 Trinchieri; Giorgio Antibodies to natural killer stimulatory factor
JPH0322973A (ja) * 1989-01-19 1991-01-31 Wan Shen-Yuan ヒトヘパトーム細胞系によるコロニー形成促進因子（ＣＳＦｓ）の構成性産生
PH27534A (en) * 1989-07-14 1993-08-18 Schering Corp Antoganists of gm-csf derived from the carboxyl terminus
WO1993017047A1 (en) 1992-02-28 1993-09-02 Board Of Regents, The University Of Texas System Compositions and methods for the treatment of thermal injury
US6004807A (en) * 1992-03-30 1999-12-21 Schering Corporation In vitro generation of human dendritic cells
US6361976B1 (en) 1992-11-24 2002-03-26 S. Christopher Bauer Co-administration of interleukin-3 mutant polypeptides with CSF'S for multi-lineage hematopoietic cell production
US7091319B1 (en) 1992-11-24 2006-08-15 Bauer S Christopher IL-3 variant hematopoiesis fusion protein
US6361977B1 (en) 1992-11-24 2002-03-26 S. Christopher Bauer Methods of using multivariant IL-3 hematopoiesis fusion protein
US6403076B1 (en) 1992-11-24 2002-06-11 S. Christopher Bauer Compositions for increasing hematopoiesis with interleukin-3 mutants
US5772992A (en) * 1992-11-24 1998-06-30 G.D. Searle & Co. Compositions for co-administration of interleukin-3 mutants and other cytokines and hematopoietic factors
US5738849A (en) * 1992-11-24 1998-04-14 G. D. Searle & Co. Interleukin-3 (IL-3) variant fusion proteins, their recombinant production, and therapeutic compositions comprising them
US6413509B1 (en) 1992-11-24 2002-07-02 S. Christopher Bauer Methods of ex-vivo expansion of hematopoietic cells using interleukin-3 mutant polypeptides with other hematopoietic growth factors
US6153183A (en) * 1992-11-24 2000-11-28 G. D. Searle & Company Co-administration of interleukin-3 mutant polypeptides with CSF's or cytokines for multi-lineage hematopoietic cell production
US6057133A (en) * 1992-11-24 2000-05-02 G. D. Searle Multivariant human IL-3 fusion proteins and their recombinant production
ES2274157T3 (es) 1993-05-12 2007-05-16 Genetics Institute, Llc Composiciones de bmp-11.
DE69331268T2 (de) * 1993-06-30 2002-06-13 Lucky, Ltd. Modifizierte-Granulocyte-Makrophage-Kolonie-stimulierender-Faktor-Gen und seine Expression in Hefe
US6027919A (en) 1993-12-07 2000-02-22 Genetics Institute, Inc. BMP-12 and BMP-13 proteins and DNA encoding them
US5599536A (en) * 1993-12-13 1997-02-04 Sandoz Ltd. Method for suppressing the acute phase response in a patient receiving IL-6 therapy
US5578301A (en) * 1993-12-14 1996-11-26 Sandoz Ltd. Method for using GM-CSF to reduce the acute phase response in a patient being administered IL-6 therapy
US6165748A (en) 1997-07-11 2000-12-26 Genetics Institute, Inc. Frazzled nucleotide sequences and expression products
US6676937B1 (en) 1998-03-09 2004-01-13 Caritas St. Elizabeth's Medical Center Of Boston Inc. Compositions and methods for modulating vascularization
DE19905501B4 (de) 1999-02-10 2005-05-19 MediGene AG, Gesellschaft für molekularbiologische Kardiologie und Onkologie Verfahren zur Herstellung eines rekombinanten Adeno-assoziierten Virus, geeignete Mittel hierzu sowie Verwendung zur Herstellung eines Arzneimittels
CA2367575A1 (en) * 1999-02-12 2000-08-17 Washington University Stimulating neutrophil function to treat inflammatory bowel disease
US6869762B1 (en) 1999-12-10 2005-03-22 Whitehead Institute For Biomedical Research Crohn's disease-related polymorphisms
AU2258601A (en) * 1999-12-10 2001-06-18 Ellipsis Biotherapeutics Corporation Ibd-related polymorphisms
US6689599B1 (en) 2000-10-20 2004-02-10 Genetics Institute, Llc Aggrecanase molecules
TWI329129B (en) 2001-02-08 2010-08-21 Wyeth Corp Modified and stabilized gdf propeptides and uses thereof
WO2003012038A2 (en) 2001-07-27 2003-02-13 Wyeth Aggrecanase molecules
EP1476545A4 (en) 2002-01-31 2006-11-29 Wyeth Corp AGGRECANASEMOLEKÜLE
PL373396A1 (en) 2002-02-05 2005-08-22 Wyeth Truncated aggrecanase molecules
JP2005534308A (ja) 2002-07-29 2005-11-17 ワイス 修飾ａｄａｍｔｓ４分子およびその使用法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4428632A (en) * 1979-08-10 1984-01-31 Thomas & Betts Corporation Coaxial cable transition connector
JPS6030654B2 (ja) * 1980-12-31 1985-07-17 株式会社林原生物化学研究所 ヒトコロニ−刺激因子の製造方法
US4438032A (en) * 1981-01-30 1984-03-20 The Regents Of The University Of California Unique T-lymphocyte line and products derived therefrom
JPH0751511B2 (ja) * 1982-03-15 1995-06-05 味の素株式会社 インターロイキン２を含有してなる癌治療剤
AU594014B2 (en) * 1984-03-21 1990-03-01 Research Corporation Technologies, Inc. Recombinant DNA molecules
ZA856108B (en) * 1984-10-29 1986-10-29 Immunex Corp Cloning of human granulocyte-macrophage colony simulating factor gene
AU588819B2 (en) * 1984-10-29 1989-09-28 Immunex Corporation Cloning of human granulocyte-macrophage colony stimulating factor gene

Also Published As

Publication number Publication date
PT80776B (pt) 1987-09-30
HK111594A (en) 1994-10-21
FI860308A (fi) 1986-01-22
UA39161C2 (uk) 2001-06-15
JPS61502682A (ja) 1986-11-20
JP2594744B2 (ja) 1997-03-26
JP2540509B2 (ja) 1996-10-02
GR851643B (no) 1985-11-26
NO179455C (no) 1996-10-09
NO1996016I1 (no) 1996-12-18
PL254400A1 (en) 1986-06-17
DK172679B1 (da) 1999-05-17
JPH06199897A (ja) 1994-07-19
IE60819B1 (en) 1994-08-10
IL94754A0 (en) 1991-04-15
KR860700264A (ko) 1986-08-01
LU88337I2 (fr) 1994-05-04
AU5497690A (en) 1990-09-13
NO314941B1 (no) 2003-06-16
IE851695L (en) 1986-01-06
SK505985A3 (en) 1999-10-08
AU628069B2 (en) 1992-09-10
NO860775L (no) 1986-03-13
AU4009089A (en) 1989-12-07
NO943300D0 (no) 1994-09-07
NO961452L (no) 1996-04-12
NO943300L (no) 1986-03-13
DK102886A (da) 1986-03-06
ATE172494T1 (de) 1998-11-15
FI108796B (fi) 2002-03-28
JPH07163351A (ja) 1995-06-27
NO307348B1 (no) 2000-03-20
NL930089I2 (nl) 1994-07-01
JPH06319557A (ja) 1994-11-22
HU208711B (en) 1993-12-28
EP0188479B1 (en) 1991-09-11
PT80776A (en) 1985-08-01
DK102886D0 (da) 1986-03-06
EP0337359A3 (en) 1990-02-07
NZ228031A (en) 1991-12-23
EP0337359B1 (en) 1998-10-21
IL75725A (en) 1993-02-21
SA94150015B1 (ar) 2004-09-04
DK168709B1 (da) 1994-05-24
JP2594768B2 (ja) 1997-03-26
CA1340852C (en) 1999-12-14
WO1986000639A1 (en) 1986-01-30
DE3588199D1 (de) 1998-11-26
NL930089I1 (nl) 1993-10-01
CA1341618C (en) 2011-07-19
ES8701226A1 (es) 1986-11-16
AU644359B2 (en) 1993-12-09
FI860308A0 (fi) 1986-01-22
NO179455B (no) 1996-07-01
AU4545685A (en) 1986-02-10
DE3584089D1 (de) 1991-10-17
NO961452D0 (no) 1996-04-12
SA94150015A (ar) 2005-12-03
KR910001809B1 (ko) 1991-03-26
ES544868A0 (es) 1986-11-16
EP0337359A2 (en) 1989-10-18
NZ212645A (en) 1990-02-26
PL153139B1 (en) 1991-03-29
IE930961L (en) 1986-01-06
DE188479T1 (de) 1987-05-21
HK1011709A1 (en) 1999-07-16
SG108991G (en) 1992-03-20
EP0188479A1 (en) 1986-07-30
AU599572B2 (en) 1990-07-26
JP2594743B2 (ja) 1997-03-26
MY102902A (en) 1993-03-31
DK59493A (da) 1993-05-21
IL75725A0 (en) 1985-11-29
DK59493D0 (da) 1993-05-21
ATE67244T1 (de) 1991-09-15
SK280265B6 (sk) 1999-10-08
DE3588199T2 (de) 1999-04-08
HUT38675A (en) 1986-06-30

Similar Documents

Publication Publication Date Title
AU644359B2 (en) Lymphokine production and purification
CA2203373A1 (en) Process for improved recombinant production of disulphide bond-containing polypeptides via a protein disulfide isomerase
EP0236978A3 (en) Production of factor xiiia by gene technology
GR3006597T3 (no)